AU2420101A - Method and composition for the treatment of pain - Google Patents
Method and composition for the treatment of painInfo
- Publication number
- AU2420101A AU2420101A AU24201/01A AU2420101A AU2420101A AU 2420101 A AU2420101 A AU 2420101A AU 24201/01 A AU24201/01 A AU 24201/01A AU 2420101 A AU2420101 A AU 2420101A AU 2420101 A AU2420101 A AU 2420101A
- Authority
- AU
- Australia
- Prior art keywords
- pain
- treatment
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17190699P | 1999-12-23 | 1999-12-23 | |
| US60171906 | 1999-12-23 | ||
| US23678500P | 2000-09-29 | 2000-09-29 | |
| US60236785 | 2000-09-29 | ||
| PCT/SE2000/002608 WO2001047524A1 (en) | 1999-12-23 | 2000-12-19 | Method and composition for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2420101A true AU2420101A (en) | 2001-07-09 |
Family
ID=26867557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU24201/01A Abandoned AU2420101A (en) | 1999-12-23 | 2000-12-19 | Method and composition for the treatment of pain |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1244453A1 (en) |
| JP (1) | JP2003518500A (en) |
| AU (1) | AU2420101A (en) |
| WO (1) | WO2001047524A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE334982T1 (en) | 2000-09-29 | 2006-08-15 | Astrazeneca Ab | 7-CHLORINE-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10- |
| WO2002026741A1 (en) * | 2000-09-29 | 2002-04-04 | Astrazeneca Ab | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN |
| ES2263661T3 (en) * | 2000-09-29 | 2006-12-16 | Astrazeneca Ab | 1,2,5,10-TETRAHYDROPIRIDAZINO (4,5-B) QUINOLIN-1,10-DIONAS AND ITS USE FOR THE TREATMENT OF PAIN. |
| EP1325005A1 (en) * | 2000-09-29 | 2003-07-09 | AstraZeneca AB | 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain |
| SE0403172D0 (en) * | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | Manufacturing process |
| DK2167458T3 (en) * | 2007-05-29 | 2018-06-18 | Intrexon Corp | CHIRAL DIACYL HYDRAZINE LIGANDS FOR MODULATING EXPRESSION OF EXOGENEOUS GENES OF AN ECDYSON RECEPTOR COMPLEX |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
-
2000
- 2000-12-19 WO PCT/SE2000/002608 patent/WO2001047524A1/en not_active Ceased
- 2000-12-19 JP JP2001548118A patent/JP2003518500A/en active Pending
- 2000-12-19 EP EP00987933A patent/EP1244453A1/en not_active Withdrawn
- 2000-12-19 AU AU24201/01A patent/AU2420101A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003518500A (en) | 2003-06-10 |
| WO2001047524A1 (en) | 2001-07-05 |
| EP1244453A1 (en) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1231887E (en) | Method and composition for the treatment of scars | |
| AU6872498A (en) | Method and composition for skin treatment | |
| AU5788300A (en) | Medical treatment method and kit | |
| AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
| AU2495200A (en) | Compositions and methods for the treatment of tumor | |
| AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2212299A (en) | Compositions and methods for the treatment of tumor | |
| AU7748000A (en) | Method and composition for the treatment of dermatologic diseases | |
| AU3784999A (en) | Methods for treatment of pain | |
| AU6056500A (en) | Process and composition for temporarily suppressing pain | |
| AU3896900A (en) | Treatment of pain | |
| AU2420101A (en) | Method and composition for the treatment of pain | |
| AU2566201A (en) | Compounds and methods for the treatment of pain | |
| HUP0300043A3 (en) | Method and composition for the treatment of pain | |
| AU2420201A (en) | Compounds and methods for the treatment of pain | |
| AU5169200A (en) | Methods and compositions for treating breakthrough pain | |
| AU4598400A (en) | Method of treatment | |
| AU2683500A (en) | Compositions for the treatment of pain | |
| IL150208A0 (en) | Compound and method for the treatment of pain | |
| AU2382601A (en) | Novel method of treatment | |
| AU2224800A (en) | Compositions and methods for the treatment of tumor | |
| AU1621501A (en) | Methods and compositions for treatment of disease | |
| AU2003200032A1 (en) | Method of treatment and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |